Table 1. Percentage average amyloid area in PPP with and without spike protein and with and without thrombin.

Naïve healthy PPP vs naïve healthy PPP + added thrombin (n=10)
P-value (Wilcoxon’s test, paired non-parametric data expressed as median [Q1 − Q3]	0.2
Median of naïve healthy samples	0.3% [0.1–0.8%]
Median of naïve control samples (+ thrombin)	0.9% [0.3–1.5%]
Naïve healthy PPP + spike protein (1 ng.ml−1) vs healthy PPP + spike protein (1 ng.ml−1) + added thrombin) (n=10)
P-value (data normally distributed; paired t test)	0.3
Mean percentage amyloid of healthy samples + spike	1.9% (±1.2%)
Mean percentage amyloid of healthy samples + spike (+ Thrombin)	2.4% (±1.3%)
Naïve healthy PPP vs healthy PPP + spike protein (1 ng.ml−1) (n=10)
P-value (Wilcoxon’s test, paired non-parametric data expressed as median [Q1 − Q3]	0.004 (*)
Median of healthy samples	0.3% [0.1–0.8%]
Median of healthy samples + spike	1.9% [1.2–2.4%]
Naïve healthy PPP + added thrombin vs healthy PPP + spike protein (1 ng.ml−1) + added thrombin) (n=10)
P-value (data normally distributed; paired t test)	0.0036 (*)
Mean percentage amyloid of control samples (+ Thrombin)	0.9% (±0.6%)
Mean percentage amyloid of control samples + spike (+ Thrombin)	2.4% (1.3%)

Statistical significance was established at P<0.05. (* = P<0.01). Data are represented as either mean ± SD or median [Q1 − Q3].